The tumour necrosis factor-alpha inhibitor adalimumab rapidly reverses the decrease in epidermal Langerhans cell density in psoriatic plaques
- 1 November 2005
- journal article
- research article
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 153 (5) , 945-953
- https://doi.org/10.1111/j.1365-2133.2005.06816.x
Abstract
The pathophysiology of psoriasis is poorly understood, and the mechanism of action of biological agents interfering with tumour necrosis factor (TNF)-alpha that improve psoriatic plaques is completely unknown. To begin to unravel the mechanism of action, cellular changes occurring in plaques following administration of adalimumab, a humanized monoclonal antibody against TNF-alpha, were investigated. Thirteen different patients underwent sequential biopsies as part of a clinical trial. Each biopsy was immunostained and evaluated to calculate the relative density of epidermal Langerhans cells (LCs) before and after treatment (days 2, 7, 28, 84). To explore the basis for reduced epidermal LC densities in plaques, a SCID-Hu animal model was utilized. Acute psoriatic lesions were created within 2 weeks by injection of superantigen-activated CD4+ T cells into engrafted symptomless skin. Compared with symptomless skin, untreated plaques had a significantly reduced density of epidermal LCs. There was a rapid increase in density of epidermal LCs in plaques following treatment with adalimumab beginning as early as day 7. The paucity of epidermal LCs in plaques was contrasted to the prominent density of LCs in other skin disorders with chronic inflammation and alterations in keratinization, including lichen planus and inflamed seborrhoeic keratosis. Rapid creation of plaques using the SCID-Hu model was accompanied by loss of epidermal LCs, indicating that diminished LC density occurs at an early stage of lesion formation. These data shed light on a new immunopathological perspective highlighting a rapid loss of epidermal LCs in acute psoriatic lesions, with sustained decreased density of LCs in chronic plaques. Furthermore, an unexpected insight into the mechanism of action was uncovered for adalimumab, in which rapid restoration of epidermal LC density was observed.Keywords
This publication has 38 references indexed in Scilit:
- Session 19: Clinical immunology of psoriasisImmunology, 2004
- Injection of Pre-Psoriatic Skin with CD4+ T Cells Induces PsoriasisThe American Journal of Pathology, 1999
- Assessment of epidermal dendritic cell markers and T‐lymphocytes in psoriasisThe Journal of Pathology, 1994
- Immunohistochemistry detects differences between lichen planus‐like keratosis, lichen planus, and lichenoid actinic keratosisJournal of Cutaneous Pathology, 1993
- Langerhans cell distribution and keratinocyte expression of HLADR in oral lichen planusJournal of Oral Pathology & Medicine, 1992
- Occurrence of Langerhans cells and expression of class II antigens on keratinocytes in malignant and benign epithelial tumors of the skin: An immunohistopathologic study with monoclonal antibodiesJournal of the American Academy of Dermatology, 1989
- Comparison of different methods for enumeration of Langerhans cells in vertical cryosections of human skinBritish Journal of Dermatology, 1988
- An assessment of Langerhans cell quantification in tissue sectionsJournal of the American Academy of Dermatology, 1984
- Langerhans Cells in Skin from Patients with Psoriasis: Quantitative and Qualitative Study of T6 and HLA-DR Antigen-Expressing Cells and Changes with Aromatic Retinoid AdministrationJournal of Investigative Dermatology, 1983
- A DEVELOPMENTAL STUDY OF THE DISTRIBUTION AND FREQUENCY OF LANGERHANS CELLS IN RELATION TO FORMATION OF PATTERNING IN MOUSE TAIL EPIDERMISJournal of Investigative Dermatology, 1977